Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug355 | Apixaban Wiki | 0.71 |
drug523 | BMS-986256 Wiki | 0.71 |
drug2619 | Milk of magnesia Wiki | 0.71 |
Name (Synonyms) | Correlation | |
---|---|---|
D000544 | Alzheimer Disease NIH | 0.22 |
D060825 | Cognitive Dysfunction NIH | 0.15 |
D055370 | Lung Injury NIH | 0.13 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0002511 | Alzheimer disease HPO | 0.22 |
HP:0001268 | Mental deterioration HPO | 0.15 |
Navigate: Correlations HPO
There are 2 clinical trials
This study assesses the clinical effectiveness of mammalian target of rapamycin (mTOR) inhibition with rapamycin in minimizing or decreasing the severity of acute lung injury/acute respiratory distress syndrome (ALI/ARDS) in participants infected with mild to moderate COVID-19 virus.
Description: The proportion of participants who survive without respiratory failure
Measure: Survival rate Time: 4 weeksDescription: The WHO ordinal scale is a measure of clinical improvement using a scale score of 0-8, where 0 indicates a better outcome and 8 indicates death: Uninfected, no clinical oor virological evidence of infection 0 Ambulatory, no limitation of activities 1 Ambulatory, limitation of activities 2 Hospitalized Mild disease, no oxygen therapy 3 Hospitalized mild disease, oxygen by mask or nasal prongs 4 Hospitalized Severe Disease, non-invasive ventilation 5 Hospitalized severe disease, intubation and mechanical ventilation 6 Hospitalized severe disease, ventilation+organ support 7 Death 8
Measure: Change in Clinical Status assessed by the World Health Organization (WHO) scale Time: Baseline to 4 weeksDescription: An ordinal scale for clinical improvement scored from 1 to 8, where 1 represents death and 8 represents recovery to discharge from hospital with no limitation on activities: Death (1) Hospitalized, on invasive mechanical ventilation of extracorporeal membrane oxygenation (ECMO) (2) Hospitalized, on non-invasive ventilation or high flow oxygen devices (3) Hospitalized, requiring supplemental oxygen (4) Hospitalized, not requiring supplemental oxygen or ongoing medical care (6) Not hospitalized, limitation on activities &/or requiring supplemental home oxygen (7) Not hospitalized, no limitation on activities (8)
Measure: Change in Clinical Status assessed by the National Institute of Allergy and Infectious Disease (NIAID) scale Time: Baseline to 4 weeksDescription: Total number of deaths during the study period
Measure: All cause mortality Time: 4 weeksDescription: Number of days on ECMO
Measure: Duration of ECMO Time: Up to 4 weeksDescription: Number of days participants are on supplemental oxygen
Measure: Duration of supplemental oxygen Time: Up to 4 weeksDescription: Days of hospitalization
Measure: Length of hospital stay Time: Up to 4 weeksDescription: Number of days until there is a negative response to the reverse transcriptase-polymerase chain reaction test (RT-PCR)
Measure: Length of time to SARS-CoV2 negativity Time: Up to 4 weeksThis study will evaluate the safety, tolerability, and feasibility of 12 month oral rapamycin treatment in older adults with amnestic mild cognitive impairment (aMCI) and early stage Alzheimer's disease (AD).
Description: Development or worsening of medical symptoms or problems
Measure: Number of adverse events Time: Baseline to 12 monthsDescription: A comprehensive metabolic panel is used to measure change in glucose level
Measure: Change in glucose level Time: Baseline to 12 monthsDescription: A comprehensive metabolic panel is used to measure change in albumin level
Measure: Change in albumin Time: Baseline to 12 monthsDescription: A comprehensive metabolic panel is used to measure change in CO2
Measure: Change in carbon dioxide or bicarbonate (CO2) Time: Baseline to 12 monthsDescription: A comprehensive metabolic panel is used to measure change in calcium levels
Measure: Change in calcium Time: Baseline to 12 monthsDescription: A lumbar puncture and blood draw will be used to evaluate levels of study drug
Measure: Central nervous system penetration of rapamycin Time: Baseline and 12 monthsDescription: Cognition will be measured using the PACC5 scale. The PACC5 is a composite score comprised of measures of global cognition, memory, and executive function. The score reflects an averaged z-score. Scores range from -3 to +3 with higher scores indicating better cognitive performance.
Measure: Change in Cognition using preclinical Alzheimer's Cognitive Composite 5 (PACC5) Time: Baseline to 12 monthsDescription: CDR is obtained through semistructured interviews of patients and informants, and cognitive functioning is rated in 6 domains of functioning: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. Each domain is rated on a 5-point scale of functioning as follows: 0, no impairment; 0.5, questionable impairment; 1, mild impairment; 2, moderate impairment; and 3, severe impairment. Domain scores are entered into an online algorithm and CDR-SOB score obtained by summing each of the domain box scores, ranging from 0 to 18. A lower score indicates better cognition.
Measure: Change in Cognition using Clinical Dementia Rating Scale sum of Boxes (CDR-SOB) Time: Baseline to 12 monthsDescription: Functional status will be measured using the functional assessment scale (FAS). The FAS is completed by a collateral source and assesses ability to complete instrumental activities of daily living. The scale has 10-items and responses range from 0-3. The total score is a sum of the individual items. The total score ranges from 0 to 30 with higher scores indicating more assistance needed.
Measure: Change in Functional status Time: Baseline to 12 monthsDescription: Symptoms will be evaluated using the Geriatric Depression Scale 15 Item (GDS-15). The GDS-15 is a self-report questionnaire with 15 items that have response options of 0 or 1. The total score is the sum of the individual items. The total score on the measure ranges between 0 to 15 with higher scores indicating more depressive symptoms.
Measure: Change in Neuropsychiatric symptoms Time: Baseline to 12 monthsDescription: Gait speed will be evaluated with an electronic gait mat
Measure: Change in Gait Speed Time: Baseline to 12 monthsDescription: Grip strength will be evaluated with a hand dynamometer
Measure: Change in Grip Strength Time: Baseline to 12 monthsDescription: Cerebrospinal fluid (CSF) levels of amyloid beta
Measure: Change in CSF amyloid beta Time: Baseline to 12 monthsDescription: Cerebral glucose metabolism is measured using fluorodeoxyglucose-Positron emission tomography (FDG-PET)
Measure: Change in cerebral glucose metabolism Time: Baseline to 12 monthsDescription: Measure of brain volumetry using MRI
Measure: Change in Brain Volumetry Time: Baseline to 12 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports